文献速递介入腹部DSACTMR

多柔比星洗脱微球经导管动脉化疗栓塞治疗反应评估:5年移植队列中的肿瘤生物学与肝细胞癌复发

Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort.
PubMed 文献 · Radiology · 2017-12-04

本回顾性分析纳入93例接受多柔比星洗脱微球经导管动脉化疗栓塞(DEB-TACE)后桥接肝移植的肝细胞癌患者,低级别肿瘤(0-2级)长期治疗反应良好者占87%,高级别肿瘤(3-4级)仅33%(P < .001);移植后随访82例中7例(9%)复发,DEB-TACE反应不佳(疾病稳定或局部进展)见于86%的复发例,且占所有疾病稳定或局部进展患者的35%(P < .001);利用移植前常规变量构建的复发风险模型一致性统计量为0.83,敏感度83.6%、特异度82.6%、阴性预测值98.4%。

要点

  • 低级别肿瘤(0-2级)DEB-TACE后长期治疗反应良好者87%,高级别肿瘤(3-4级)仅33%(P < .001)。
  • 移植后复发7例(9%),其中86%的复发例存在DEB-TACE反应不佳(疾病稳定或局部进展)。
  • 基于移植前常规变量的复发风险模型一致性统计量0.83,敏感度83.6%、特异度82.6%、阴性预测值98.4%。

核心结论

  • DEB-TACE治疗反应与肿瘤生物学及移植后复发风险相关,可能与非移植后肝细胞癌复发相关。

研究设计与样本

  • 经机构审查委员会批准、符合HIPAA的回顾性分析,纳入2011年7月7日至2016年5月16日5年期间连续93例(男73例、女20例;平均年龄59.6岁,范围23-72岁)接受DEB-TACE后行肝移植的患者。

诊断标准与关键数值

  • DEB-TACE反应基于改良实体瘤疗效评价标准(mRECIST)评估;低级别肿瘤(0、1或2级)长期治疗反应良好者87%(完全缓解49%、部分缓解38%、疾病稳定或局部进展13%),高级别肿瘤(3或4级)33%(完全缓解0%、部分缓解33%、疾病稳定或局部进展67%)(P < .001)。

临床应用与阅片要点

  • 作者认为DEB-TACE反应与肿瘤生物学和移植后复发风险相关,可能与非移植后肝细胞癌复发相关;利用移植前常规变量构建的验证模型一致性统计量0.83,敏感度83.6%、特异度82.6%、阴性预测值98.4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretransplantation model for posttransplantation recurrence risk. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective analysis, 93 consecutive patients (73 male, 20 female; mean age, 59.6 years; age range, 23-72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a 5-year period from July 7, 2011, to May 16, 2016. DEB-TACE response was based on modified Response Evaluation Criteria in Solid Tumors. Imaging responses and posttransplantation recurrence were compared with demographics, liver function, basic immune markers, treatment dose, and tumor morphology. Treatment response and recurrence were analyzed with uni- and multivariate statistics, as well as internal validation and propensity score matching of factors known to affect recurrence to assess independent effects of DEB-TACE response on recurrence. Results Low-grade tumors (grade 0, 1, or 2) demonstrated a favorable long-term treatment response in 87% of patients (complete response, 49%; partial response, 38%; stable disease [SD] or local disease progression [DP], 13%) versus 33% of high-grade tumors (grade 3 or 4) (complete response, 0%; partial response, 33%; SD or DP, 67%) (P < .001). Of the 93 patients who underwent treatment, 82 were followed-up after transplantation (mean duration, 757 days). Recurrence occurred in seven (9%) patients (mean time after transplantation, 635 days). Poor response to DEB-TACE (SD or DP) was present in 86% of cases and accounted for 35% of all patients with SD or DP (P < .001). By using only variables routinely available prior to liver transplantation, a validated model of posttransplantation recurrence risk was produced with a concordance statistic of 0.83. The validated model shows sensitivity of 83.6%, specificity of 82.6%, and negative predictive value of 98.4%, which are pessimistic estimates. Conclusion Response to DEB-TACE is correlated with tumor biology and patients at risk for posttransplantation recurrence, and it may be associated with HCC recurrence after liver transplantation. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Sandow TA, Arndt SE, Albar AA, et al. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort. Radiology. 2017. PMID: 29206595. doi:10.1148/radiol.2017170731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。